VistaGen TherapeuticsVTGN
VTGN
About: Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Employees: 57
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
625% more call options, than puts
Call options by funds: $29K | Put options by funds: $4K
0.51% less ownership
Funds ownership: 55.75% [Q4 2024] → 55.24% (-0.51%) [Q1 2025]
9% less funds holding
Funds holding: 54 [Q4 2024] → 49 (-5) [Q1 2025]
13% less capital invested
Capital invested by funds: $44.9M [Q4 2024] → $39M (-$5.83M) [Q1 2025]
40% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 20
56% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 9
Research analyst outlook
We haven’t received any recent analyst ratings for VTGN.
Financial journalist opinion
Based on 3 articles about VTGN published over the past 30 days
Neutral
Business Wire
2 weeks ago
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead the evaluation of strategic opportunities to advance Vistagen's pherine platform toward potential commercial la.
Neutral
Seeking Alpha
3 weeks ago
Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2025 Earnings Conference Call June 17, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Mark Adrian McPartland - Senior Vice President of Investor Relations Shawn K. Singh - President, CEO & Director Conference Call Participants Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Lin Tsai - Jefferies LLC, Research Division Myles Robert Minter - William Blair & Company L.L.C.
Neutral
Business Wire
3 weeks ago
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corporate update. “This was a defining year for Vistagen, marked by significant progress in our registration-directed PALISADE program for fa.
Neutral
Business Wire
1 month ago
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Tuesday, June 17, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 ended March 31, 2025, and provide a corporate updat.
Neutral
Business Wire
1 month ago
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today provides an update on the timeline for the ongoing clinical trials in its U.S. registration-directed PALISADE Phase 3 Program evaluating fasedienol for acute treatment of social anxiety disorder (SAD). The Company's PALISADE-.
Neutral
Business Wire
1 month ago
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at Jefferies 2025 Global Life Sciences Conference in New York. Vistagen's President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat on Thursday, June 5, at 11:40 a.m. Ea.
Neutral
Business Wire
1 month ago
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the American Society of Clinical Psychopharmacology (ASCP) Conference in Scottsdale, Arizona from May 27-30, 2025. The Company's poster presentations will explore the age of onset of social anxiety dis.
Neutral
Business Wire
2 months ago
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented new data on social anxiety disorder (SAD) at the 2025 Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada. The Company's poster presentations examined the age of onset of SAD in participants in.
Neutral
Business Wire
3 months ago
Vistagen to Present at the 2025 Anxiety and Depression Association Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas, Nevada from April 3 to 5, 2025. The Company's poster presentations will explore the age of onset of social anxiety diso.
Neutral
Business Wire
4 months ago
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that management will participate in Stifel's 2025 Virtual CNS Forum. Vistagen's President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation on Tuesday, March 18, 2025, at 12 p.m.
Charts implemented using Lightweight Charts™